A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates With Enterovirus Sepsis
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Neonatal enterovirus sepsis has high mortality. Antiviral therapy is not available. METHODS: Neonates with suspected enterovirus sepsis (hepatitis, coagulopathy, and/or myocarditis) with onset at ≤15 days of life were randomized 2:1 to receive oral pleconaril or placebo for 7 days. Serial virologic (oropharynx, rectum, urine, serum), clinical, pharmacokinetic, and safety evaluations were performed. RESULTS: Sixty-one subjects were enrolled (43 treatment, 18 placebo), of whom 43 were confirmed enterovirus infected (31 treatment, 12 placebo). There was no difference in day 5 oropharyngeal culture positivity (primary endpoint; 0% in both groups). However, enterovirus-infected subjects in the treatment group became culture negative from all anatomic sites combined faster than placebo group subjects (median 4.0 versus 7.0 days, P = .08), and fewer subjects in the treatment group remained polymerase chain reaction (PCR)-positive from the oropharynx when last sampled (23% versus 58%, P = .02; median, 14.0 days). By intent to treat, 10/43 (23%) subjects in the treatment group and 8/18 (44%) in the placebo group died (P = .02 for 2-month survival difference); among enterovirus-confirmed subjects, 7/31 (23%) in the treatment group died versus 5/12 (42%) in the placebo group (P = .26). All pleconaril recipients attained concentrations greater than the IC90 after the first study day, but 38% were less than the IC90 during the first day of treatment. One subject in the treatment group and three in the placebo group had treatment-related adverse events. CONCLUSIONS: Shorter times to culture and PCR negativity and greater survival among pleconaril recipients support potential efficacy and warrant further evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Enteroviral Meningitis: Natural History and Outcome of Pleconaril Therapy
Desmond, R. A., Accortt, N. A., Talley, L., Villano, S. A., Soong, S.-J., & Whitley, R. J. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00227-06 · Cited by 154 · cited 1×
“In studies of EV meningitis, EV infections in immunocompromised hosts, and picornavirus upper respiratory tract infections [7–13] and in a phase 1 study in neonates and uncontrolled case reports and case series in newborns [14, 15], pleconaril was generally well tolerated, with suggestion of benefit in some studies.”
BackgroundSelf-citationDouble blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis
ABZUG, M. J., CLOUD, G., BRADLEY, J., SÁNCHEZ, P. J., ROMERO, J., POWELL, D., LEPOW, M., MANI, C., CAPPARELLI, E. V., BLOUNT, S., et al. (2003) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000059765.92623.70 · Cited by 138
Self-citation
Cited by
Myocarditis and inflammatory cardiomyopathy: current evidence and future directions
Tschöpe, C., Ammirati, E., Bozkurt, B., Caforio, A. L. P., Cooper, L. T., Felix, S. B., Hare, J. M., Heidecker, B., Heymans, S., Hübner, N., et al. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00435-x · Cited by 1,217
Epidemiology and Immune Pathogenesis of Viral Sepsis
Lin, G.-L., McGinley, J. P., Drysdale, S. B., & Pollard, A. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02147 · Cited by 351
“The drug recently completed a small phase 2 clinical trial (248); however, it is no longer under development and is not available, even for compassionate use.”
BackgroundEnterovirus and parechovirus infection in children: a brief overview
de Crom, S. C. M., Rossen, J. W. A., van Furth, A. M., & Obihara, C. C. (2016) · European Journal of Pediatrics · doi:10.1007/s00431-016-2725-7 · Cited by 192
Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial
Krogvold, L., Mynarek, I. M., Ponzi, E., Mørk, F. B., Hessel, T. W., Roald, T., Lindblom, N., Westman, J., Barker, P., Hyöty, H., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02576-1 · Cited by 55
Viral sepsis: diagnosis, clinical features, pathogenesis, and clinical considerations
Xu, J.-Q., Zhang, W.-Y., Fu, J.-J., Fang, X.-Z., Gao, C.-G., Li, C., Yao, L., Li, Q.-L., Yang, X.-B., Ren, L.-H., et al. (2024) · Military Medical Research · doi:10.1186/s40779-024-00581-0 · Cited by 37
Metadata
- Authors
- Abzug, M. J., Michaels, M. G., Wald, E., Jacobs, R. F., Romero, J. R., Sánchez, P. J., Wilson, G., Krogstad, P., Storch, G. A., Lawrence, R., Shelton, M., Palmer, A., Robinson, J., Dennehy, P., Sood, S. K., Cloud, G., Jester, P., Acosta, E. P., Whitley, R., & Kimberlin, D.
- Venue
- Journal of the Pediatric Infectious Diseases Society
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-16
- Volume
- 5
- Issue
- 1
- Pages
- 53-62
- ISSN
- 2048-7193 (ISSN-L)
- 2048-7207
- OpenAlex
- W2117951318
- Cited by
- 155
- References
- 2
- FWCI
- 9.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates With Enterovirus Sepsis. https://app.cochat.ai/papers/10.1093/jpids/piv015
- The paper
- Abzug, M. J., Michaels, M. G., Wald, E., Jacobs, R. F., Romero, J. R., Sánchez, P. J., Wilson, G., Krogstad, P., Storch, G. A., Lawrence, R., Shelton, M., Palmer, A., Robinson, J., Dennehy, P., Sood, S. K., Cloud, G., Jester, P., Acosta, E. P., Whitley, R., & Kimberlin, D. (2016). A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates With Enterovirus Sepsis. Journal of the Pediatric Infectious Diseases Society. https://doi.org/10.1093/jpids/piv015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.